Voya Investment Management LLC Acquires 1,884 Shares of Wave Life Sciences Ltd (WVE)

Voya Investment Management LLC lifted its holdings in shares of Wave Life Sciences Ltd (NASDAQ:WVE) by 37.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 6,873 shares of the company’s stock after purchasing an additional 1,884 shares during the period. Voya Investment Management LLC’s holdings in Wave Life Sciences were worth $263,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Wells Fargo & Company MN grew its position in Wave Life Sciences by 5,257.8% in the 2nd quarter. Wells Fargo & Company MN now owns 360,633 shares of the company’s stock worth $13,794,000 after purchasing an additional 353,902 shares in the last quarter. BlackRock Inc. grew its position in Wave Life Sciences by 37.0% in the 2nd quarter. BlackRock Inc. now owns 1,201,655 shares of the company’s stock worth $45,963,000 after purchasing an additional 324,659 shares in the last quarter. BB Biotech AG grew its position in Wave Life Sciences by 27.0% in the 2nd quarter. BB Biotech AG now owns 1,137,885 shares of the company’s stock worth $43,524,000 after purchasing an additional 241,789 shares in the last quarter. Janus Henderson Group PLC grew its position in Wave Life Sciences by 11.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,518,758 shares of the company’s stock worth $58,092,000 after purchasing an additional 160,545 shares in the last quarter. Finally, FMR LLC grew its position in Wave Life Sciences by 6.1% in the 2nd quarter. FMR LLC now owns 1,036,878 shares of the company’s stock worth $39,661,000 after purchasing an additional 59,879 shares in the last quarter. 83.42% of the stock is owned by institutional investors.

WVE opened at $47.58 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.11 and a current ratio of 6.11. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -12.36 and a beta of 1.00. Wave Life Sciences Ltd has a twelve month low of $21.20 and a twelve month high of $56.00.

Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Thursday, August 9th. The company reported ($1.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.88). The company had revenue of $4.88 million during the quarter, compared to analysts’ expectations of $7.38 million. Wave Life Sciences had a negative net margin of 1,473.26% and a negative return on equity of 91.88%. As a group, research analysts anticipate that Wave Life Sciences Ltd will post -4.99 earnings per share for the current fiscal year.

A number of equities research analysts have issued reports on the stock. Mizuho set a $65.00 price objective on shares of Wave Life Sciences and gave the stock a “buy” rating in a research report on Friday, June 29th. BidaskClub downgraded shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 28th. HC Wainwright set a $49.00 price objective on shares of Wave Life Sciences and gave the stock a “buy” rating in a research report on Friday, August 10th. Stifel Nicolaus assumed coverage on shares of Wave Life Sciences in a research report on Monday, August 6th. They issued a “buy” rating and a $56.00 price objective for the company. Finally, ValuEngine raised shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Wave Life Sciences has an average rating of “Buy” and an average target price of $58.40.

In other Wave Life Sciences news, insider Chris Francis sold 11,575 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $56.00, for a total value of $648,200.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Chandra Vargeese sold 3,000 shares of the business’s stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $55.00, for a total transaction of $165,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,075 shares of company stock worth $2,435,700. Corporate insiders own 44.20% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Wave Life Sciences Ltd (NASDAQ:WVE).

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply